{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:10:06Z","timestamp":1765267806482,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.urology.2006.04.021","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T11:16:16Z","timestamp":1158664576000},"page":"674-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model"],"prefix":"10.1016","volume":"68","author":[{"given":"Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sunamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Ishidoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2006.04.021_bib1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer: a 10-year followup","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.04.021_bib2","first-page":"1393","article-title":"Frequent association of p53 gene mutation in invasive bladder cancer","volume":"52","author":"Fujimoto","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2006.04.021_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00005392-200101000-00073","article-title":"Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes","volume":"165","author":"Sourvinos","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.04.021_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ijc.2910530513","article-title":"Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression","volume":"53","author":"Xu","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2006.04.021_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.urology.2006.04.021_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2006.04.021_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.urology.2006.04.021_bib8","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1128\/JVI.73.7.5333-5344.1999","article-title":"p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication","volume":"73","author":"Harada","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.urology.2006.04.021_bib9","first-page":"4434","article-title":"E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer","volume":"63","author":"Fukuda","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2006.04.021_bib10","first-page":"5348","article-title":"Presence and location of TP53 mutation determines pattern of CDKN2A\/ARF pathway inactivation in bladder cancer","volume":"58","author":"Markl","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2006.04.021_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ijc.2910140207","article-title":"Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder: detection by a 3-H-proline microcytotoxicity test","volume":"14","author":"Bean","year":"1974","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2006.04.021_bib12","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/nar\/23.19.3816","article-title":"Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase","volume":"23","author":"Kanegae","year":"1995","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urology.2006.04.021_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/10430340050015978","article-title":"Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus","volume":"11","author":"Motoi","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.urology.2006.04.021_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1006\/bbrc.1996.5975","article-title":"Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal","volume":"230","author":"Yoshida","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.urology.2006.04.021_bib15","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2006.04.021_bib16","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2006.04.021_bib17","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/sj.onc.1207321","article-title":"A novel E1A-E1B mutant adenovirus induces glioma regression in vivo","volume":"23","author":"Gomez-Manzano","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2006.04.021_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.cgt.7700090","article-title":"Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse","volume":"6","author":"Wood","year":"1999","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.urology.2006.04.021_bib19","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1073\/pnas.87.7.2775","article-title":"Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells","volume":"87","author":"Horowitz","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urology.2006.04.021_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urology.2006.04.021_bib21","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","article-title":"Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells","volume":"72","author":"Rothmann","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.urology.2006.04.021_bib22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/80466","article-title":"Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)","volume":"6","author":"Ries","year":"2000","journal-title":"Nat Med"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506006121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506006121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:44:47Z","timestamp":1758764687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429506006121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0090429506006121"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2006.04.021","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2006.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}